My Analysis
Intercept Pharmaceuticals (ICPT) became biotechnologically famous in 2014 with its stock blasting off financially to a place no liver therapeutics stock had ever been. Since then, this mid-cap ($3.52B) biopharma has had to deal with the clinical scrutiny that typically occurs after the famous moment has eased off. I first provide overview of why Intercept found clinical fame and then the clinical scrutiny that it cannot "shake off" at least until the imminent results are announced and proven successful with good safety and tolerability signals.
The Data Safety Monitoring Board recommended